Cardiol CEO David Elsley unpacks FDA Orphan Drug Designation for Cardiol

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) made headlines earlier in the week when it revealed that the US Food and Drug Administration had granted its lead drug candidate CardiolRx orphan drug designation, indicating potential efficacy in treating recurrent pericarditis. The designation provides benefits such as marketing exclusivity and fee reduction, and the company's share prices have surged as a result. Cardiol's focus on addressing the symptoms of recurrent pericarditis, including chest pain and red ...